For some families, this is a daily reality due to rare genetic disorders. One such condition is Sanfilippo syndrome, which creates significant hurdles for affected children and their families.
The biotechnology company, Ultragenyx, has reported a successful fourth quarter and full year 2024 financial results ...
Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant ...
WWMT Grand Rapids/Lansing on MSN14d
Annual Kozminski Memorial game honors fallen officer while aiding family in needThe Grand Rapids Police Department will face the Kentwood Police Department in just one of the matchups scheduled for the ...
Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...
Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...
Ultragenyx Pharmaceutical RARE reported new findings from an ongoing, pivotal study of its investigational candidate, UX111 (ABO-102) AAV gene therapy, for Sanfilippo syndrome type A (MPS IIIA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback